JP7649442B2 - シングルセルごとの特定の核酸のコピー数の検出方法 - Google Patents
シングルセルごとの特定の核酸のコピー数の検出方法 Download PDFInfo
- Publication number
- JP7649442B2 JP7649442B2 JP2022571563A JP2022571563A JP7649442B2 JP 7649442 B2 JP7649442 B2 JP 7649442B2 JP 2022571563 A JP2022571563 A JP 2022571563A JP 2022571563 A JP2022571563 A JP 2022571563A JP 7649442 B2 JP7649442 B2 JP 7649442B2
- Authority
- JP
- Japan
- Prior art keywords
- chromosome
- cells
- pcr
- cell
- deletion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108020004707 nucleic acids Proteins 0.000 title claims description 37
- 102000039446 nucleic acids Human genes 0.000 title claims description 37
- 150000007523 nucleic acids Chemical class 0.000 title claims description 37
- 210000004027 cell Anatomy 0.000 claims description 326
- 210000000349 chromosome Anatomy 0.000 claims description 242
- 239000000523 sample Substances 0.000 claims description 173
- 238000006243 chemical reaction Methods 0.000 claims description 142
- 108020004414 DNA Proteins 0.000 claims description 114
- 238000012217 deletion Methods 0.000 claims description 66
- 230000037430 deletion Effects 0.000 claims description 64
- 238000001514 detection method Methods 0.000 claims description 62
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 58
- 230000003321 amplification Effects 0.000 claims description 56
- 239000000126 substance Substances 0.000 claims description 47
- 108091093088 Amplicon Proteins 0.000 claims description 46
- 208000036878 aneuploidy Diseases 0.000 claims description 46
- 108020005196 Mitochondrial DNA Proteins 0.000 claims description 43
- 231100001075 aneuploidy Toxicity 0.000 claims description 31
- 206010061765 Chromosomal mutation Diseases 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 25
- 230000001605 fetal effect Effects 0.000 claims description 21
- 210000004369 blood Anatomy 0.000 claims description 19
- 239000008280 blood Substances 0.000 claims description 19
- 230000008774 maternal effect Effects 0.000 claims description 15
- 230000036961 partial effect Effects 0.000 claims description 13
- 230000004544 DNA amplification Effects 0.000 claims description 12
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 11
- 230000006037 cell lysis Effects 0.000 claims description 11
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 10
- 210000003855 cell nucleus Anatomy 0.000 claims description 10
- 238000010839 reverse transcription Methods 0.000 claims description 10
- 210000004381 amniotic fluid Anatomy 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 208000036282 monosomy chromosome 8 Diseases 0.000 claims description 9
- 239000007850 fluorescent dye Substances 0.000 claims description 7
- 238000012224 gene deletion Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 6
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- 230000002934 lysing effect Effects 0.000 claims description 5
- 238000011002 quantification Methods 0.000 claims description 4
- 208000026817 47,XYY syndrome Diseases 0.000 claims description 3
- 101150106774 9 gene Proteins 0.000 claims description 3
- 208000009575 Angelman syndrome Diseases 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000000398 DiGeorge Syndrome Diseases 0.000 claims description 3
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- 201000006360 Edwards syndrome Diseases 0.000 claims description 3
- 206010014950 Eosinophilia Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 208000017924 Klinefelter Syndrome Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 101150105382 MET gene Proteins 0.000 claims description 3
- 101150022024 MYCN gene Proteins 0.000 claims description 3
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 201000009928 Patau syndrome Diseases 0.000 claims description 3
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 206010044686 Trisomy 13 Diseases 0.000 claims description 3
- 208000006284 Trisomy 13 Syndrome Diseases 0.000 claims description 3
- 208000007159 Trisomy 18 Syndrome Diseases 0.000 claims description 3
- 206010044688 Trisomy 21 Diseases 0.000 claims description 3
- 208000026928 Turner syndrome Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 206010056894 XYY syndrome Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 claims description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 206010053884 trisomy 18 Diseases 0.000 claims description 3
- 208000026485 trisomy X Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 101150054472 HER2 gene Proteins 0.000 claims description 2
- 108700020302 erbB-2 Genes Proteins 0.000 claims description 2
- 206010011385 Cri-du-chat syndrome Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 38
- 210000004748 cultured cell Anatomy 0.000 description 34
- 238000005259 measurement Methods 0.000 description 33
- 208000026487 Triploidy Diseases 0.000 description 20
- 206010028980 Neoplasm Diseases 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 15
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 13
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 13
- 238000010586 diagram Methods 0.000 description 12
- 230000003322 aneuploid effect Effects 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 210000004180 plasmocyte Anatomy 0.000 description 10
- 230000035772 mutation Effects 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 239000007787 solid Substances 0.000 description 7
- 206010064571 Gene mutation Diseases 0.000 description 6
- 238000012937 correction Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 201000000050 myeloid neoplasm Diseases 0.000 description 6
- 208000007660 Residual Neoplasm Diseases 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 208000030454 monosomy Diseases 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 101150076800 B2M gene Proteins 0.000 description 3
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 3
- 208000031404 Chromosome Aberrations Diseases 0.000 description 3
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 3
- 101150112014 Gapdh gene Proteins 0.000 description 3
- 208000033495 Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000003053 chromosome 5q deletion syndrome Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000007847 digital PCR Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 101150015830 nd1 gene Proteins 0.000 description 3
- 238000003793 prenatal diagnosis Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 208000020584 Polyploidy Diseases 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 208000037280 Trisomy Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 210000001840 diploid cell Anatomy 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000013412 genome amplification Methods 0.000 description 2
- 210000003783 haploid cell Anatomy 0.000 description 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 2
- 239000000138 intercalating agent Substances 0.000 description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 2
- 229960004942 lenalidomide Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000005382 thermal cycling Methods 0.000 description 2
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 206010061764 Chromosomal deletion Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 108700012912 MYCN Proteins 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 208000002774 Paraproteinemias Diseases 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101150059736 SRY gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000011304 droplet digital PCR Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020216149 | 2020-12-25 | ||
| JP2020216149 | 2020-12-25 | ||
| PCT/JP2021/047619 WO2022138736A1 (ja) | 2020-12-25 | 2021-12-22 | シングルセルごとの特定の核酸のコピー数の検出方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2022138736A1 JPWO2022138736A1 (https=) | 2022-06-30 |
| JPWO2022138736A5 JPWO2022138736A5 (https=) | 2023-09-07 |
| JP7649442B2 true JP7649442B2 (ja) | 2025-03-21 |
Family
ID=82157024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022571563A Active JP7649442B2 (ja) | 2020-12-25 | 2021-12-22 | シングルセルごとの特定の核酸のコピー数の検出方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240043929A1 (https=) |
| EP (1) | EP4269614A4 (https=) |
| JP (1) | JP7649442B2 (https=) |
| KR (1) | KR20230107662A (https=) |
| CN (1) | CN116802314A (https=) |
| CA (1) | CA3206327A1 (https=) |
| TW (1) | TWI906439B (https=) |
| WO (1) | WO2022138736A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116356005B (zh) * | 2023-04-28 | 2023-09-26 | 宁波熙宁检测技术有限公司 | 一种检测car-t细胞拷贝数的组合物及其用途 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015508655A (ja) | 2012-02-14 | 2015-03-23 | コーネル ユニバーシティー | 組み合わせたヌクレアーゼ反応、連結反応、およびポリメラーゼ反応を用いて核酸配列、発現、またはコピー変化を相対的に定量するための方法 |
| JP2015533079A (ja) | 2012-08-13 | 2015-11-19 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 生物学的成分を検出するための方法およびシステム |
| WO2018025856A1 (ja) | 2016-08-02 | 2018-02-08 | 学校法人武庫川学院 | 簡便な遺伝子検査法およびコピー数計測法ならびにその支援技術 |
| JP2020000011A (ja) | 2018-06-25 | 2020-01-09 | 株式会社理研ジェネシス | ゲノムｄｎａ中の標的領域のコピー数検出方法及び試薬キット |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8574842B2 (en) * | 2009-12-22 | 2013-11-05 | The Board Of Trustees Of The Leland Stanford Junior University | Direct molecular diagnosis of fetal aneuploidy |
| US20130130930A1 (en) | 2011-11-17 | 2013-05-23 | Bhairavi Parikh | Methods and devices for obtaining and analyzing cells |
| JP6234542B1 (ja) | 2016-12-27 | 2017-11-22 | 株式会社 TL Genomics | 胎児細胞由来染色体ｄｎａの取得方法 |
| KR20180102242A (ko) | 2017-03-06 | 2018-09-17 | 주식회사 우리은행 | 금융 자동화 기기의 비대면 채널 사용자 인증 방법 및 시스템 |
| US11254975B2 (en) * | 2018-05-24 | 2022-02-22 | National Center For Child Health And Development | Method of amplifying a polynucleotide of interest |
| WO2021200749A1 (ja) * | 2020-04-01 | 2021-10-07 | 株式会社 ＴＬ Ｇｅｎｏｍｉｃｓ | 細胞の染色体又はその部分のコピー数を検出する方法 |
-
2021
- 2021-12-22 US US18/258,836 patent/US20240043929A1/en active Pending
- 2021-12-22 KR KR1020237020216A patent/KR20230107662A/ko active Pending
- 2021-12-22 WO PCT/JP2021/047619 patent/WO2022138736A1/ja not_active Ceased
- 2021-12-22 EP EP21910876.8A patent/EP4269614A4/en active Pending
- 2021-12-22 CN CN202180086085.8A patent/CN116802314A/zh active Pending
- 2021-12-22 JP JP2022571563A patent/JP7649442B2/ja active Active
- 2021-12-22 CA CA3206327A patent/CA3206327A1/en active Pending
- 2021-12-23 TW TW110148433A patent/TWI906439B/zh active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015508655A (ja) | 2012-02-14 | 2015-03-23 | コーネル ユニバーシティー | 組み合わせたヌクレアーゼ反応、連結反応、およびポリメラーゼ反応を用いて核酸配列、発現、またはコピー変化を相対的に定量するための方法 |
| JP2015533079A (ja) | 2012-08-13 | 2015-11-19 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 生物学的成分を検出するための方法およびシステム |
| WO2018025856A1 (ja) | 2016-08-02 | 2018-02-08 | 学校法人武庫川学院 | 簡便な遺伝子検査法およびコピー数計測法ならびにその支援技術 |
| JP2020000011A (ja) | 2018-06-25 | 2020-01-09 | 株式会社理研ジェネシス | ゲノムｄｎａ中の標的領域のコピー数検出方法及び試薬キット |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230107662A (ko) | 2023-07-17 |
| JPWO2022138736A1 (https=) | 2022-06-30 |
| TWI906439B (zh) | 2025-12-01 |
| EP4269614A4 (en) | 2025-06-18 |
| WO2022138736A1 (ja) | 2022-06-30 |
| US20240043929A1 (en) | 2024-02-08 |
| CA3206327A1 (en) | 2022-06-30 |
| EP4269614A1 (en) | 2023-11-01 |
| TW202239967A (zh) | 2022-10-16 |
| CN116802314A (zh) | 2023-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hindson et al. | High-throughput droplet digital PCR system for absolute quantitation of DNA copy number | |
| JP5032304B2 (ja) | 染色体異常の検出 | |
| US8574842B2 (en) | Direct molecular diagnosis of fetal aneuploidy | |
| EP2759601A1 (en) | Gene copy number variation measurement method | |
| Oscorbin et al. | Multiplex ddPCR assay for screening copy number variations in BRCA1 gene | |
| US10968487B2 (en) | Oligonucleotides and methods for detecting KRAS and PIK3CA mutations | |
| JP2016146845A (ja) | デジタル検体分析 | |
| GB2488358A (en) | Enrichment of foetal DNA in maternal plasma | |
| EP4462436A2 (en) | Multiplex drop-off digital polymerase chain reaction methods | |
| US20250346949A1 (en) | Methods and kits for determining the efficiency of plasma separation from whole blood | |
| CN110964814A (zh) | 用于核酸序列变异检测的引物、组合物及方法 | |
| CN106939334B (zh) | 一种孕妇血浆中胎儿dna含量的检测方法 | |
| JP2013090622A (ja) | 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用キット | |
| US20240068039A1 (en) | Multi-vector detection of variant sequences | |
| JP7649442B2 (ja) | シングルセルごとの特定の核酸のコピー数の検出方法 | |
| Decraene et al. | Single droplet digital polymerase chain reaction for comprehensive and simultaneous detection of mutations in hotspot regions | |
| Stitz et al. | Clinical implementation of a noninvasive, multi-analyte droplet digital PCR test to screen for androgen receptor alterations | |
| CA3225580A1 (en) | Methods and compositions for nucleic acid analysis | |
| Wong et al. | Rapid detection of the UGT1A1 single nucleotide polymorphism G211A using real‐time PCR with Taqman minor groove binder probes | |
| WO2018186687A1 (ko) | 생물학적 시료의 핵산 품질을 결정하는 방법 | |
| CN102453766A (zh) | 多态性检测用探针、多态性检测方法、药效评价方法及多态性检测用试剂盒 | |
| TW201940702A (zh) | 量化標的基因的突變型等位基因負擔的方法 | |
| CN117795091A (zh) | 用于快速多重筛选和监测npm1突变的组合物和方法 | |
| Oscorbin et al. | Multiplex droplet digital PCR for 22q11. 2 microdeletions screening and DiGeorge syndrome diagnostics | |
| EP4092134A1 (en) | Method and system for dna detection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230621 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230621 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240820 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241018 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250107 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250205 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7649442 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |